Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Anixa Biosciences, Inc. - Common Stock (NQ:ANIX)

3.260 -0.040 (-1.21%)
Streaming Delayed Price Updated: 2:24 PM EST, Jan 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Anixa Biosciences, Inc. - Common Stock

< Previous 1 2 3 Next >
Water Tower Research Publishes Initiation of Coverage Report on Anixa Biosciences, Inc., “Anixa’s T-Cell Innovations Show Breakthrough Potential in Solid Tumors”
Via TheNewswire.com
News headline image
3 Under-the-Radar Biotechs Under $5 That Could Soar 200% ↗
3 biotech stocks under $5 with cancer, obesity, and psychedelic therapies offer speculative investors high-risk, high-reward potential: HOTH, SILO, and ANIX. 
Via MarketBeat
News headline image
EXCLUSIVE: Anixa Biosciences Receives Key US Patent Nod For Breast Cancer Vaccine Patent ↗
Anixa secures USPTO patent for its breast cancer vaccine using α-lactalbumin, enhancing its IP portfolio and expanding future immunotherapy options. 
Via Benzinga
Topics Intellectual Property
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
Recap: Anixa Biosciences Q1 Earnings ↗
 
Via Benzinga
News headline image
6 Analysts Have This to Say About Anixa Biosciences ↗
 
Via Benzinga
News headline image
The Latest Analyst Ratings for Anixa Biosciences ↗
 
Via Benzinga
News headline image
Expert Ratings for Anixa Biosciences ↗
 
Via Benzinga
News headline image
EXCLUSIVE: Anixa Biosciences Inks Letter of Intent with Austria-Based VERDI Solutions To Develop AI-Guided Personalized Cancer Vaccines ↗
Anixa Biosciences signed a letter of intent with VERDI Solutions to develop AI-powered personalized and off-the-shelf cancer vaccines, with U.S. trials planned. 
Via Benzinga
News headline image
EXCLUSIVE: Anixa Biosciences Poised To Receive US Patent For Ovarian Cancer Vaccine ↗
Anixa Biosciences secured a USPTO patent allowance for its ovarian cancer vaccine, strengthening its IP position and advancing its clinical development. 
Via Benzinga
Topics Intellectual Property
News headline image
This ACNB Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday ↗
 
Via Benzinga
News headline image
iAccess Alpha's Buyside Best Ideas Virtual Winter Conference December 10-11, 2024
Via ACCESSWIRE
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
Anixa Biosciences And 3 Other Stocks Under $5 Insiders Are Buying ↗
 
Via Benzinga
News headline image
EXCLUSIVE: FDA Approves Anixa Biosciences' Individual Patient Trial Application For Ovarian Cancer CAR-T Therapy ↗
FDA Approves Anixa Biosciences' Ovarian Cancer CAR-T Therapy for Individual Patient Trial. Moffit Cancer Center receives approval for a second dose in an ongoing Phase I trial showing early promising... 
Via Benzinga
News headline image
EXCLUSIVE: Anixa Biosciences Finds Stock Undervalued, Launches $5M Stock Buyback Program ↗
Anixa Biosciences announces $5 million share repurchase program due to undervalued stock. Partnership with Cleveland Clinic for cancer vaccines. 
Via Benzinga
News headline image
ANIX Stock Earnings: Anixa Biosciences Beats EPS for Q2 2024 ↗
ANIX stock results show that Anixa Biosciences beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
7 Penny Biotech Stocks to Triple Your Investment ↗
Biotech penny stocks offer the chance to triple your investments and require an appetite for risk in order to capture returns. 
Via InvestorPlace
Anixa Biosciences, Inc. (NASDAQ: ANIX) Featured in Coverage of the EF Hutton Annual Global Conference
Via Investor Brand Network
News headline image
Sidoti Events, LLC's Virtual May Micro-Cap Conference
Via ACCESSWIRE
Anixa Biosciences (NASDAQ:ANIX) Gains Attention for Its Innovative Cancer Therapies Amid Biopharma Sector Growth
Via AB Newswire
News headline image
Sidoti Events, LLC's Virtual January Micro-Cap Conference
Via ACCESSWIRE
News headline image
Anixa Biosciences, A New Type Of Biotech Company: Could It Disrupt The Cancer Landscape? ↗
Anixa Biosciences (NASDAQ: ANIX) is an interesting, undiscovered biotech company that seeks to disrupt the cancer landscape by working with some highly credible partners. The company is undiscovered... 
Via Benzinga
News headline image
3 Biotech Stocks to Turn $5,000 Into $1 Million: December 2023 ↗
Some of the most explosive opportunities can be found in biotech stocks. In fact, as we head into New Year 2024, here are three to consider. 
Via InvestorPlace
News headline image
Anixa Biosciences Reveals Updated Data From Breast Cancer Vaccine Trial, Says 'Exceeded Expectations' ↗
Anixa Biosciences Inc (NASDAQ: ANIX) announced new and updated results from the Phase 1 trial of its breast cancer vaccine.  
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
The 3 Most Undervalued Cheap Stocks to Buy in September 2023 ↗
These cheap stocks to buy are the ones for long term growth and high returns in your investment portfolio. 
Via InvestorPlace
News headline image
Could Anixa Biosciences (NASDAQ:ANIX) Be Developing The Vaccine To End One Of The Deadliest Types Of Breast Cancer?
Via ACCESSWIRE
News headline image
Could Anixa Biosciences (NASDAQ: ANIX) Be Developing The Vaccine To End One Of The Deadliest Types Of Breast Cancer? ↗
Cancer is a disease that affects millions of people around the world. Historically, cancer vaccines have not been very successful in treating or preventing the disease. However, recent research on the... 
Via Benzinga
News headline image
Anixa Biosciences And 2 Other Penny Stocks Insiders Are Aggressively Buying ↗
The Dow Jones edged higher on Friday, recording gains for the tenth straight session. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects.... 
Via Benzinga
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.